Dr. McKenzie on the Rationale for Concurrent Tissue and Liquid Biopsies in Lung Cancer

Video

In Partnership With:

Andrew McKenzie, PhD, discusses the rationale to utilize concurrent tissue- and liquid-based biopsies in lung cancer.

Andrew McKenzie, PhD, director, Personalized Medicine, Sarah Cannon Research Institute, discusses the rationale to utilize concurrent tissue- and liquid-based biopsies in lung cancer.

Tissue- and plasma-based biopsies are different assays that can often yield different molecular results, says McKenzie. Typically, liquid biopsy is utilized in patients with difficult-to-biopsy or bone-only disease. Additionally, plasma-based testing may be a useful longitudinal tool for monitoring molecular markers, McKenzie explains.

Currently, tissue-based testing remains the gold standard with regard to next-generation sequencing, McKenzie says. Moreover, tissue biopsies that can detect RNA fusions and other markers that are difficult to identify by plasma-based testing are useful tools.

Ultimately, tissue and liquid biopsies are not interchangeable and concurrent use of these molecular tests could be helpful in identifying clinically relevant markers, concludes McKenzie.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS